MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) (NASDAQ:MBX)
· seekingalpha.com
MBX Biosciences is upgraded to Buy on strong Phase 2 canvuparatide data, Phase 3 path, and cash-rich catalysts. Click for this MBX stock update.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...